Brand name
Solu-Medrol, the original
We didn’t find a savings card or cash price from Solu-Medrol’s maker. Ask the pharmacy for Solu-Medrol’s cash price. With insurance, ask what your plan charges.
Generic name: methylprednisolone
Used for: Severe allergic conditions (such as asthma, drug reactions) · Arthritis flares, lupus and other rheumatic diseases · Multiple sclerosis (MS) flares · Skin diseases such as pemphigus or Stevens-Johnson syndrome · Flare-ups of ulcerative colitis or Crohn’s disease · Some blood disorders (anemias, low platelets) · Brain swelling from a tumor or brain surgery · Easing symptoms of leukemia and lymphoma · 7 more
Ask for the cash price
Generic methylprednisolone
No pharmacy we check posts a price for it.
A regular generic has the same active ingredient as Solu-Medrol, and the FDA requires it to work the same way.
Solu-Medrol, the original
We didn’t find a savings card or cash price from Solu-Medrol’s maker. Ask the pharmacy for Solu-Medrol’s cash price. With insurance, ask what your plan charges.
There isn’t one.
Same active ingredient as Solu-Medrol. Fillers and dyes can differ.
4 companies sell a generic of Solu-Medrol that the FDA rates a substitute. A pharmacy fills whichever one it stocks. To get a certain maker, ask for it by name; most pharmacies can order it in a day or two.
Has lactose · Made by Hikma Farmaceutica Portugal
40 mg
| Package | NDC |
|---|---|
| Carton of 25 | 72572-097-25 |
125 mg
| Package | NDC |
|---|---|
| Carton of 25 | 72572-098-25 |
Inactive ingredients: sodium phosphate, monobasic, anhydrous, sodium phosphate, dibasic, lactose monohydrate, sodium hydroxide
Has lactose · Made by Tianjin Kingyork Pharmaceuticals
1 g/16 mL White to off-white
| Package | NDC |
|---|---|
| Carton of 16 mL | 43598-130-74 |
40 mg/mL White to off-white
| Package | NDC |
|---|---|
| Carton of 25 mL | 43598-127-25 |
125 mg/2 mL White to offi-white
| Package | NDC |
|---|---|
| Carton of 50 mL | 43598-129-25 |
500 mg/8 mL White to off-white
| Package | NDC |
|---|---|
| Carton of 8 mL | 43598-128-11 |
Inactive ingredients: sodium phosphate, monobasic, monohydrate, sodium phosphate, dibasic, anhydrous, lactose monohydrate
Has lactose
1 g/16 mL
| Package | NDC |
|---|---|
| Carton of 16 mL | 63323-265-30 |
40 mg/mL
| Package | NDC |
|---|---|
| Tray of 25 mL | 63323-255-03 |
125 mg/2 mL
| Package | NDC |
|---|---|
| Tray of 50 mL | 63323-258-03 |
Inactive ingredients: sodium phosphate, monobasic, anhydrous, sodium phosphate, dibasic, anhydrous, sodium hydroxide, benzyl alcohol, lactose monohydrate
Has lactose
1 g
| Package | NDC |
|---|---|
| Vial of 1 | 0143-9851-01 |
40 mg
| Package | NDC |
|---|---|
| Carton of 25 | 0143-9753-25 |
125 mg
| Package | NDC |
|---|---|
| Carton of 25 | 0143-9754-25 |
500 mg
| Package | NDC |
|---|---|
| Vial of 1 | 0143-9850-01 |
Inactive ingredients: sodium phosphate, monobasic, anhydrous, sodium phosphate dibasic dihydrate, sodium phosphate, dibasic, lactose monohydrate, sodium hydroxide
Who sells it: FDA and Medicaid records, updated weekly. Each maker’s page, card and program is from its own site.
“Before you fill my Solu-Medrol, can you tell me what I’d pay for the brand and for a generic?”
Paying cash? Ask for each one’s cash price. With insurance, ask what your plan charges for each.
When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of SOLU-MEDROL Sterile Powder is indicated as follows:
Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions.
Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome).
Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.
Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis.
Hematologic disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, selected cases of secondary thrombocytopenia.
Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy.
Neoplastic diseases: For the palliative management of leukemias and lymphomas.
Nervous System: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy.
Ophthalmic diseases: Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids.
Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus.
Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis.
Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus.
Source: the FDA label for Solu-Medrol (Pharmacia & Upjohn Company LLC), June 25, 2026. Full label on DailyMed
Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/solu-medrol/